In today’s ACT Brief, we examine how the Verana Health-COTA merger is evolving real-world data use, the FDA’s new framework for individualized ultra-rare disease therapies, and what a decade of ...

“Designing treatments unique to individual patients has always been the promised goal of personalized medicine. After 25 years the FDA has, for the first time, outlined a framework to facilitate these ...

In this episode of the Applied Clinical Trials Podcast, C.K. Wang, MD, chief medical officer at COTA; and Sujay Jadhav, CEO ...

In today’s ACT Brief, we explore how Bayesian trial designs are gaining traction in rare disease research, what priorities clinical operations leaders should focus on in 2026, and how rare disease ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

In today’s ACT Brief, we explore how sites are taking the lead on AI adoption to strengthen feasibility and enrollment, why earlier cross-functional alignment is critical in data-driven trials, and ...

Jonathan Andrus, co-CEO of CRIO, discusses how governance across the data lifecycle, site-focused technology adoption, and scalable AI-enabled workflows will define operational readiness in 2026.

Enhance predictability and quality in design, planning and trial delivery by leveraging novel tools and approaches ...

At SCOPE Summit 2026, site leaders shared how AI is transforming feasibility, patient identification, and enrollment ...

Andrus: Collaboration really needs to start earlier—during protocol development, not after the fact. Clinical operations, data management, and technology teams need to align on source workflows before ...

In a new FAQ article on ACT, evolving outsourcing strategies reflect growing demand for flexibility as trial complexity increases. Hybrid models that blend full-service and functional approaches are ...